The Right to a Trial?
July 6, 2007 7:48 AM Subscribe
The fight over an experimental cancer therapy gets ugly. The FDA's decision to delay approval of Provenge, an experimental therapy for advanced prostate cancer, has incensed patients and advocacy groups, who have launched a sophisticated lobbying effort calling for the drug's approval and questioning the motives of critics. Of course, investors in Dendreon, the creators of Provenge, have a strong financial interest in seeing Provenge approved. The New Yorker covers the complicated issues surrounding patient access to experimental therapies in this story.
This thread has been archived and is closed to new comments